The investment objective of the Scheme is to achieve long-term capital growth.
Name | % Net Assets |
---|---|
Fisher Scientific | 13.6% |
Tyco International | 10.4% |
Gilead Sciences | 8.8% |
Accenture | 7.2% |
Biomet | 6.9% |
C.H. Robinson Worldwide | 6.6% |
Home Depot | 6.0% |
Bed Bath & Beyond | 5.8% |
Allergan | 5.4% |
L-3 Communications | 4.7% |
Key | % Net Assets |
---|---|
![]() |
13.6% |
![]() |
10.4% |
![]() |
8.8% |
![]() |
7.2% |
![]() |
60% |
Date | 15-Apr-2025 |
---|---|
Bid | 2.23p |
Offer | 2.40p |
Currency | GBP |
Change | 2.32p |
% | n/a |
YTD change | -0.23p |
YTD % | -9.12% |
Fund Inception | 01/03/1999 |
---|---|
Fund Manager | David Tyerman |
TER | - |
Minimum Investment | |
---|---|
Initial | £10000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 7.00% |
Annual Mang't | 1.00% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | -0.00 |
You are here: research